The Technical AnalystExchange: STO Sector: Healthcare Industry: Biotechnology
ExpreS2ion Biotech Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.98% SEK1.408
America/New_York / 17 mai 2024 @ 11:29
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 72.38 mill |
| EPS: | -1.780 |
| P/E: | -0.790 |
| Earnings Date: | May 30, 2024 |
| SharesOutstanding: | 51.41 mill |
| Avg Daily Volume: | 0.148 mill |
| RATING 2024-05-17 |
|---|
| C |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Sell | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.790 | sector: PE 19.76 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -0.790 | industry: PE 491.84 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
SEK-0.472 (-133.52%) SEK-1.880 |
| Date: 2024-05-18 |
| Expected Trading Range (DAY) |
|---|
|
SEK 1.087 - 1.733 ( +/- 22.91%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | SEK1.408 (-0.98% ) |
| Volume | 0.0806 mill |
| Avg. Vol. | 0.148 mill |
| % of Avg. Vol | 54.43 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For EXPRS2.ST
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
EXPRS2.ST
ExpreS2ion Biotech Holding AB (publ), through its subsidiary, ExpreS2 ion Biotechnologies ApS, develops and produces complex proteins for vaccines and diagnostics in Denmark. The company develops capsid virus-like particle COVID-19 vaccine, which is in Phase II clinical trial. It also develops influenza and breast cancer vaccine, which is in Phase II clinical trial, as well as develops malaria vaccine. In addition, the company licenses its ExpreS2 platform to research institutes and pharmaceutical companies. ExpreS2ion Biotech Holding AB (publ) was founded in 2015 is based in Horsholm, Denmark.